BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 64.3%

Neg 0% Neu 0% Pos 64.3%

BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.